Literature DB >> 3873931

Intravitreal toxicity of hydroxyacyclovir (BW-B759U), a new antiviral agent.

J Pulido, G A Peyman, T Lesar, J Vernot.   

Abstract

We investigated the toxicity of the antiviral compound hydroxyacyclovir (9-[hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine, or BW-B759U), following intravitreal injection in the rabbit. Intravitreal doses of 10, 20, 40, 80, 100, 200, and 400 micrograms produced no discernible ophthalmoscopic or histologic changes. Intravitreal doses of 40, 200, and 400 micrograms produced no changes in the electroretinography B-waves. The low level of retinal toxicity and excellent median inhibitory dose values of intravitreal BW-B759U against cytomegalovirus suggest its potential therapeutic utility in the treatment of cytomegalovirus retinitis.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3873931     DOI： 10.1001/archopht.1985.01050060100036

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


  9 in total

1.  Intravitreal ganciclovir in CMV retinitis: case report.

Authors:  M L Harris; M B Mathalone
Journal:  Br J Ophthalmol       Date:  1989-05       Impact factor: 4.638

2.  Ocular toxicity of multiple intravitreal DHPG injections.

Authors:  M O Yoshizumi; D Lee; V Vinci; S Fajardo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

3.  Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits.

Authors:  Joseph M Harrison; Randolph D Glickman; Charles S Ballentine; Yolanda Trigo; Melanie A Pena; Pearl Kurian; Laura K Najvar; Neeru Kumar; Ankit H Patel; William E Sponsel; John R Graybill; William C Lloyd; Margaret M Miller; Gianmarco Paris; Fernando Trujillo; Aaron Miller; Robert Melendez
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

4.  Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression.

Authors:  G L Daikos; J Pulido; S B Kathpalia; G G Jackson
Journal:  Br J Ophthalmol       Date:  1988-07       Impact factor: 4.638

Review 5.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

6.  Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial.

Authors:  M Díaz-Llopis; M J Martos; E España; M Cervera; A O Vila; A Navea; F J Molina; F J Romero
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

Review 7.  Rational acyclovir therapy in herpetic eye disease.

Authors:  M G Falcon
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

8.  Retinal and Corneal Toxicity and Pharmacokinetic Analysis of Intraocular Injection of Ganciclovir in Rabbit Eyes.

Authors:  Bin-Jia Sun; Rong-Mei Peng; Qing Lu; Jing Hong
Journal:  J Ophthalmol       Date:  2019-05-07       Impact factor: 1.909

9.  Vitreous pharmacokinetics and electroretinographic findings after intravitreal injection of acyclovir in rabbits.

Authors:  Francisco Max Damico; Mariana Ramos Scolari; Gabriela Lourençon Ioshimoto; Beatriz Sayuri Takahashi; Armando da Silva Cunha; Sílvia Ligório Fialho; Daniela Maria Bonci; Fabio Gasparin; Dora Fix Ventura
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.